Online inquiry

IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1678MR)

This product GTTS-WQ1678MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL1B gene. The antibody can be applied in Atherosclerosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000576.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3553
UniProt ID P01584
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1678MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12458MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NKTR-214
GTTS-WQ14798MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-70
GTTS-WQ14503MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RYI-018
GTTS-WQ14219MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RG-6107
GTTS-WQ9231MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ6893MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA E-6011
GTTS-WQ12220MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ7875MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GSK-2398852
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW